S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
Is SoundHound Voice AI the Next Big Thing?
Warning: Biden’s Big Blackout is Coming (Ad)
CVS Health Corporation Is Coiled And Ready To Spring Higher 
Double Meat: Beyond Meat Could Be 2023’s Next Two-Bagger
Warning: Biden’s Big Blackout is Coming (Ad)
3 Solar-Energy Stocks Setting Up In Bullish Bases
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
Putin's boneheaded mistake could make Americans INCREDIBLY RICH! (Ad)pixel
TG Therapeutics Stock 300% Rally Has Legs Yet
Daqo New Energy Charged Up For New Highs
S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
Is SoundHound Voice AI the Next Big Thing?
Warning: Biden’s Big Blackout is Coming (Ad)
CVS Health Corporation Is Coiled And Ready To Spring Higher 
Double Meat: Beyond Meat Could Be 2023’s Next Two-Bagger
Warning: Biden’s Big Blackout is Coming (Ad)
3 Solar-Energy Stocks Setting Up In Bullish Bases
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
Putin's boneheaded mistake could make Americans INCREDIBLY RICH! (Ad)pixel
TG Therapeutics Stock 300% Rally Has Legs Yet
Daqo New Energy Charged Up For New Highs
S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
Is SoundHound Voice AI the Next Big Thing?
Warning: Biden’s Big Blackout is Coming (Ad)
CVS Health Corporation Is Coiled And Ready To Spring Higher 
Double Meat: Beyond Meat Could Be 2023’s Next Two-Bagger
Warning: Biden’s Big Blackout is Coming (Ad)
3 Solar-Energy Stocks Setting Up In Bullish Bases
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
Putin's boneheaded mistake could make Americans INCREDIBLY RICH! (Ad)pixel
TG Therapeutics Stock 300% Rally Has Legs Yet
Daqo New Energy Charged Up For New Highs
S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
Is SoundHound Voice AI the Next Big Thing?
Warning: Biden’s Big Blackout is Coming (Ad)
CVS Health Corporation Is Coiled And Ready To Spring Higher 
Double Meat: Beyond Meat Could Be 2023’s Next Two-Bagger
Warning: Biden’s Big Blackout is Coming (Ad)
3 Solar-Energy Stocks Setting Up In Bullish Bases
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
Putin's boneheaded mistake could make Americans INCREDIBLY RICH! (Ad)pixel
TG Therapeutics Stock 300% Rally Has Legs Yet
Daqo New Energy Charged Up For New Highs
NASDAQ:IMGN

ImmunoGen - IMGN Stock Forecast, Price & News

$4.55
-0.22 (-4.61%)
(As of 02/8/2023 12:00 AM ET)
Add
Compare
Today's Range
$4.55
$4.80
50-Day Range
$4.14
$5.47
52-Week Range
$3.10
$6.63
Volume
1.99 million shs
Average Volume
3.08 million shs
Market Capitalization
$1.00 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.11

ImmunoGen MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.57 Rating Score
Upside/​Downside
166.2% Upside
$12.11 Price Target
Short Interest
Bearish
8.13% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.85
Upright™ Environmental Score
News Sentiment
0.32mentions of ImmunoGen in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.94) to ($0.91) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.13 out of 5 stars

Medical Sector

436th out of 1,026 stocks

Pharmaceutical Preparations Industry

206th out of 504 stocks

IMGN stock logo

About ImmunoGen (NASDAQ:IMGN) Stock

ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded on March 27, 1981 and is headquartered in Waltham, MA.

Receive IMGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ImmunoGen and its competitors with MarketBeat's FREE daily newsletter.

IMGN Stock News Headlines

Company News for Dec 30, 2022
My No. 1 dividend stock for a LIFETIME of income.
Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century!  I think it's a crying shame folks don't know how powerful dividends are.
Will ImmunoGen (NASDAQ:IMGN) Spend Its Cash Wisely?
My No. 1 dividend stock for a LIFETIME of income.
Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century!  I think it's a crying shame folks don't know how powerful dividends are.
ImmunoGen (IMGN) Q3 Loss Wider, Sales Beat, '22 View Up
Should You Buy ImmunoGen (IMGN) Ahead of Earnings?
See More Headlines
Receive IMGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ImmunoGen and its competitors with MarketBeat's FREE daily newsletter.

IMGN Company Calendar

Last Earnings
10/29/2021
Today
2/09/2023
Next Earnings (Estimated)
2/24/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:IMGN
CUSIP
45253H10
Employees
106
Year Founded
1981

Price Target and Rating

Average Stock Price Forecast
$12.11
High Stock Price Forecast
$22.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+166.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

Net Income
$-139,300,000.00
Net Margins
-210.33%
Pretax Margin
-210.33%

Debt

Sales & Book Value

Annual Sales
$95.61 million
Book Value
$1.61 per share

Miscellaneous

Free Float
213,378,000
Market Cap
$1.00 billion
Optionable
Optionable
Beta
0.85

Social Links


Key Executives

  • Mark Joseph EnyedyMark Joseph Enyedy
    President, Chief Executive Officer & Director
  • Renee Lentini
    VP-Finance, Chief Financial & Accounting Officer
  • Anna Berkenblit
    Chief Medical Officer & Senior Vice President
  • Thomas Ryll
    Senior Vice President-Technical Operations
  • Michael J. Vasconcelles
    EVP-Research, Development & Medical Affairs













IMGN Stock - Frequently Asked Questions

Should I buy or sell ImmunoGen stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ImmunoGen in the last twelve months. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IMGN shares.
View IMGN analyst ratings
or view top-rated stocks.

What is ImmunoGen's stock price forecast for 2023?

7 brokerages have issued 12-month price targets for ImmunoGen's shares. Their IMGN share price forecasts range from $5.00 to $22.00. On average, they predict the company's share price to reach $12.11 in the next year. This suggests a possible upside of 166.2% from the stock's current price.
View analysts price targets for IMGN
or view top-rated stocks among Wall Street analysts.

How have IMGN shares performed in 2023?

ImmunoGen's stock was trading at $4.96 at the beginning of 2023. Since then, IMGN stock has decreased by 8.3% and is now trading at $4.55.
View the best growth stocks for 2023 here
.

When is ImmunoGen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, February 24th 2023.
View our IMGN earnings forecast
.

How were ImmunoGen's earnings last quarter?

ImmunoGen, Inc. (NASDAQ:IMGN) announced its quarterly earnings data on Friday, October, 29th. The biotechnology company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.01. The biotechnology company had revenue of $9.20 million for the quarter, compared to analysts' expectations of $19.03 million. ImmunoGen had a negative trailing twelve-month return on equity of 75.89% and a negative net margin of 210.33%. ImmunoGen's revenue was down 49.5% compared to the same quarter last year. During the same period last year, the business posted ($0.13) EPS.

What guidance has ImmunoGen issued on next quarter's earnings?

ImmunoGen issued an update on its FY 2022 earnings guidance on Friday, November, 18th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $80.00 million-$90.00 million, compared to the consensus revenue estimate of $80.22 million.

What is Mark J. Enyedy's approval rating as ImmunoGen's CEO?

16 employees have rated ImmunoGen Chief Executive Officer Mark J. Enyedy on Glassdoor.com. Mark J. Enyedy has an approval rating of 64% among the company's employees.

What other stocks do shareholders of ImmunoGen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ImmunoGen investors own include Pfizer (PFE), NVIDIA (NVDA), Micron Technology (MU), Immunomedics (IMMU), Advanced Micro Devices (AMD), AbbVie (ABBV), Gilead Sciences (GILD), OPKO Health (OPK), AT&T (T) and Dynavax Technologies (DVAX).

What is ImmunoGen's stock symbol?

ImmunoGen trades on the NASDAQ under the ticker symbol "IMGN."

Who are ImmunoGen's major shareholders?

ImmunoGen's stock is owned by many different institutional and retail investors. Top institutional investors include Pinnacle Associates Ltd. (0.60%), Pinnacle Associates Ltd. (0.60%), UBS Group AG (0.43%), Fisher Asset Management LLC (0.39%), Swiss National Bank (0.22%) and Hennion & Walsh Asset Management Inc. (0.21%). Insiders that own company stock include Craig Barrows, David G Foster, Mark J Enyedy and Thomas Ryll.
View institutional ownership trends
.

How do I buy shares of ImmunoGen?

Shares of IMGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ImmunoGen's stock price today?

One share of IMGN stock can currently be purchased for approximately $4.55.

How much money does ImmunoGen make?

ImmunoGen (NASDAQ:IMGN) has a market capitalization of $1.00 billion and generates $69.86 million in revenue each year. The biotechnology company earns $-139,300,000.00 in net income (profit) each year or ($0.82) on an earnings per share basis.

How many employees does ImmunoGen have?

The company employs 106 workers across the globe.

Does ImmunoGen have any subsidiaries?
The following companies are subsidiares of ImmunoGen: Hurricane LLC, ImmunoGen BioPharma (Ireland) Limited, ImmunoGen Europe Limited, and ImmunoGen Securities Corp..
Read More
How can I contact ImmunoGen?

ImmunoGen's mailing address is 830 WINTER ST, WALTHAM MA, 02451. The official website for the company is www.immunogen.com. The biotechnology company can be reached via phone at (781) 895-0600, via email at courtney.okonek@immunogen.com, or via fax at 781-895-0611.

This page (NASDAQ:IMGN) was last updated on 2/9/2023 by MarketBeat.com Staff